Neuroscience News and Research

RSS

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

Mood, behavioral problems after stressful interpersonal events: LPFC function may be a risk-factor

Think back to your last fight with someone you love. How did you feel afterwards? How did you behave? Conflict with a loved one often leaves a person feeling terrible and then behaving badly. So much so that these scenarios have become soap opera clich-s. After an argument, one partner may brood, slam the door, and then drive to a local bar to drown their sorrows in alcohol. These dramas rarely have happy endings. Given these stereotypes, how do people control their emotional reactions and prevent emotional storms and their attendant use of intoxicating substances?

3 Mar 2010

MJFF for Parkinson's Research awards $500,000 grant to neuroscientist at Mayo Clinic

For his work contributing to a potential new treatment approach for Parkinson's disease, the Michael J. Fox Foundation for Parkinson's Research has awarded a $500,000 grant to a neuroscientist at the Mayo Clinic campus in Florida.

3 Mar 2010

Informative workshop on multiple sclerosis

Physicians, nurses, and physician assistants in the Portland, Oregon, area who treat and care for patients with multiple sclerosis (MS) are invited to attend "Recognizing and Treating Multiple Sclerosis in the Primary Care Setting," an informative free CME/CE half-day lecture and workshop.

3 Mar 2010

Scientists uncover vital clue that could steer research into nervous system disorders

Scientists at the Queensland Brain Institute have uncovered a vital clue into how the brain is wired, which could eventually steer research into nervous system disorders such as Parkinson's disease and cognitive disorders including autism.

3 Mar 2010

AstraZeneca drafts five principles for companies engaged in social media

AstraZeneca today asked the U.S. Food and Drug Administration (FDA) to adopt guidance that will enable AstraZeneca and others to fully engage in real-time, social media conversations that responsibly provide accurate, balanced information on medicines from a known, identifiable and reliable source.

2 Mar 2010

Clot-busting drug therapy after stroke beneficial for women

New research shows women who don't receive a clot-busting drug after a stroke fare worse than men who are not treated. The study is published in the March 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Mar 2010

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Sigma-Aldrich® today unveiled its new Sigma® Life Science brand and website platform, designed to elevate the Company's current focus on biology and provide a single destination where researchers can access deep biological knowledge and market-leading products and technologies.

2 Mar 2010

Researchers uncover new explanation for the spread of tau protein within human brain

A team of researchers at UMass Lowell has found a new mechanism by which a key protein associated with Alzheimer's disease can spread within the human brain.

2 Mar 2010

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers at the University of Nebraska Medical Center have taken a significant step forward in developing a vaccination approach to reverse the neurological damage seen with Parkinson's disease.

2 Mar 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

1 Mar 2010

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.

1 Mar 2010

[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment

Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.

1 Mar 2010

Screening crucial for Triple A and more awareness needed

On Feb. 22, the day after America watched some of its strongest hearts compete in Vancouver on the 30th anniversary of the “Miracle on Ice” hockey game, a lucky patient at El Camino Hospital was recuperating from his own miracle.

1 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

Body repairs itself through microvesicles: New hope for tissue regeneration

Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.

27 Feb 2010

For people who carry common gene variants, smoking increases risk of aneurysm

For people who carry common gene variants, cigarette smoking greatly increases the risk that a blood vessel in the brain will weaken and balloon out - called an aneurysm - which could be life-threatening if it ruptures, according to research presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Neurogenesis linked to drug addiction and relapse

Researchers at UT Southwestern Medical Center hope they have begun paving a new pathway in the fight against drug dependence. Their hypothesis - that increasing the normally occurring process of making nerve cells might prevent addiction - is based on a rodent study demonstrating that blocking new growth of specific brain nerve cells increases vulnerability for cocaine addiction and relapse.

27 Feb 2010

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Complementary approaches to Alzheimer's research were recognized as four scientists received the prestigious MetLife Foundation Awards for Medical Research in Alzheimer's Disease in Washington, D.C.

26 Feb 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

Neuroscience News and Research

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Mood, behavioral problems after stressful interpersonal events: LPFC function may be a risk-factor

MJFF for Parkinson's Research awards $500,000 grant to neuroscientist at Mayo Clinic

Informative workshop on multiple sclerosis

Scientists uncover vital clue that could steer research into nervous system disorders

AstraZeneca drafts five principles for companies engaged in social media

Clot-busting drug therapy after stroke beneficial for women

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Researchers uncover new explanation for the spread of tau protein within human brain

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment

Screening crucial for Triple A and more awareness needed

Precise immune disturbances leading to Coeliac disease: More insight

Body repairs itself through microvesicles: New hope for tissue regeneration

For people who carry common gene variants, smoking increases risk of aneurysm

Neurogenesis linked to drug addiction and relapse

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

Neuroscience - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News